MA54653A - Modulateurs du récepteur de cxcr7 pipéridine - Google Patents

Modulateurs du récepteur de cxcr7 pipéridine

Info

Publication number: MA54653A
Authority: MA; Morocco
Prior art keywords: cxcr7; piperidine; receptor modulators; modulators; receptor
Prior art date: 2016-07-28

Application number

MA054653A

Other languages

English (en)

Other versions

MA54653B1 (fr

Inventor

Hamed Aissaoui

Philippe Guerry

Francois Lehembre

Julien Pothier

Laetitia Pouzol

Sylvia Richard-Bildstein

Shuguang Yuan

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-28

Filing date

2017-07-27

Publication date

2021-12-29

2017-07-27 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2021-12-29 Publication of MA54653A publication Critical patent/MA54653A/fr

2023-04-28 Publication of MA54653B1 publication Critical patent/MA54653B1/fr

Links

102100022716 Atypical chemokine receptor 3 Human genes 0.000 title 1
101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA54653A 2016-07-28 2017-07-27 Modulateurs du récepteur de cxcr7 pipéridine MA54653B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP2016068052		2016-07-28

Publications (2)

Publication Number	Publication Date
MA54653A true MA54653A (fr)	2021-12-29
MA54653B1 MA54653B1 (fr)	2023-04-28

Family

ID=59656027

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA45782A MA45782B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine
MA54653A MA54653B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA45782A MA45782B1 (fr)	2016-07-28	2017-07-27	Modulateurs du récepteur de cxcr7 pipéridine

Country Status (32)

Country	Link
US (2)	US10752620B2 (fr)
EP (2)	EP3490986B1 (fr)
JP (2)	JP6655754B2 (fr)
KR (2)	KR102497095B1 (fr)
CN (2)	CN110563717B (fr)
AR (2)	AR109180A1 (fr)
AU (2)	AU2017302079B2 (fr)
CA (1)	CA3032017C (fr)
CL (2)	CL2019000169A1 (fr)
CY (1)	CY1125016T1 (fr)
DK (2)	DK3798217T3 (fr)
EA (2)	EA037507B1 (fr)
ES (2)	ES2905755T3 (fr)
FI (1)	FI3798217T3 (fr)
HR (2)	HRP20230313T1 (fr)
HU (2)	HUE057315T2 (fr)
IL (2)	IL264424B (fr)
LT (2)	LT3798217T (fr)
MA (2)	MA45782B1 (fr)
MX (2)	MX383804B (fr)
MY (2)	MY198113A (fr)
NZ (1)	NZ751006A (fr)
PH (2)	PH12021552605A1 (fr)
PL (2)	PL3798217T3 (fr)
PT (2)	PT3490986T (fr)
RS (2)	RS64130B1 (fr)
SG (2)	SG10201906942PA (fr)
SI (2)	SI3490986T1 (fr)
TW (3)	TWI691497B (fr)
UA (2)	UA122987C2 (fr)
WO (1)	WO2018019929A1 (fr)
ZA (1)	ZA201901256B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019145460A1 (fr) *	2018-01-26	2019-08-01	Idorsia Pharmaceuticals Ltd	Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide
JP7749552B2 (ja) *	2019-10-31	2025-10-06	イドルシア・ファーマシューティカルズ・リミテッド	Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
AU2021405511A1 (en) *	2020-12-22	2023-06-22	Luxembourg Institute Of Health (Lih)	Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
EP4326257A4 (fr) *	2021-04-19	2025-03-12	ChemoCentryx, Inc.	Azétidinyl-acétamides utilisés comme inhibiteurs de cxcr7
CA3226468A1 (fr)	2021-08-02	2023-02-09	Andrew Edmunds	Derives de pyrazole microbiocides
AU2022356017B2 (en)	2021-10-01	2024-05-30	Nextgen Bioscience Co., Ltd.	Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same
JP2024546927A (ja)	2021-12-17	2024-12-26	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺微生物性ピラゾール誘導体
EP4238970A1 (fr) *	2022-03-03	2023-09-06	InterAx Biotech AG	Modulateurs de ackr3 et leurs utilisations
CN115403510B (zh) *	2022-08-11	2023-04-25	南方医科大学	一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
TW202434579A (zh)	2022-11-16	2024-09-01	瑞士商先正達農作物保護股份公司	殺微生物的四氫異喹啉衍生物
WO2024115512A1 (fr)	2022-11-30	2024-06-06	Syngenta Crop Protection Ag	Dérivés de tétrahydroisoquinoline microbiocides
TW202439972A (zh)	2022-11-30	2024-10-16	瑞士商先正達農作物保護股份公司	殺真菌組成物
PY2403614A (es)	2023-01-27	2025-09-11	Syngenta Crop Protection Ag	Derivados de pirazol microbiocidas
AR131665A1 (es)	2023-02-01	2025-04-16	Syngenta Crop Protection Ag	Composiciones fungicidas
PY2447478A (es)	2023-06-14	2025-03-18	Syngenta Crop Protection Ag	Composiciones fungicidas
PY24116120A (es)	2024-01-03	2025-07-30	Pi Industries Ltd	Compuestos de pirazol para combatir hongos fitopatógenos
PY24116080A (es)	2024-01-03	2025-08-04	Pi Industries Ltd	Amidas heterociclicas biciclicas para combatir hongos fitopatógenos
WO2025163143A1 (fr)	2024-02-02	2025-08-07	Syngenta Crop Protection Ag	Dérivés de pyrazole microbiocides
WO2025172368A1 (fr)	2024-02-13	2025-08-21	Syngenta Crop Protection Ag	Dérivés de (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]méthanone destinés à être utilisés en tant que fongicides
WO2026030052A1 (fr)	2024-07-31	2026-02-05	Fmc Corporation	Azoles substitués fongicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040102324A1 (en) *	2002-02-28	2004-05-27	Annis Gary David	Heterocyclic diamide invertebrate pest control agents
EP1565436B1 (fr)	2002-11-27	2012-04-25	Incyte Corporation	Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
TW200526626A (en)	2003-09-13	2005-08-16	Astrazeneca Ab	Chemical compounds
US7115646B2 (en)	2003-10-08	2006-10-03	Bristol Myers Squibb, Co.	Cyclic diamines and derivatives as factor Xa inhibitors
JP4058106B2 (ja) *	2005-02-18	2008-03-05	アストラゼネカアクチボラグ	抗菌性のピペリジン誘導体
CA2742515C (fr) *	2008-11-04	2017-07-11	Chemocentryx, Inc.	Modulateurs 1,4-diazepane de cxcr7
JP6094578B2 (ja)	2011-06-09	2017-03-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (fr) *	2011-12-09	2013-06-13	Cadila Healthcare Limited	Composés inhibiteurs de rénine
AR091516A1 (es)	2012-06-22	2015-02-11	Actelion Pharmaceuticals Ltd	Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
MX359651B (es) *	2012-11-29	2018-10-05	Chemocentryx Inc	Antagonistas de cxcr7.
MA38679B1 (fr) *	2013-05-30	2019-12-31	Idorsia Pharmaceuticals Ltd	Modulateurs du récepteur de cxcr7
CN105705489B (zh)	2013-09-04	2019-04-26	百时美施贵宝公司	用作免疫调节剂的化合物
HUE038169T2 (hu)	2013-09-06	2018-09-28	Aurigene Discovery Tech Ltd	1,2,4-Oxadiazol származékok mint immunomodulátorok
WO2015044900A1 (fr)	2013-09-27	2015-04-02	Aurigene Discovery Technologies Limited	Composés immunomodulateurs thérapeutiques
CA2960280A1 (fr) *	2014-09-10	2016-03-17	Epizyme, Inc.	Composes piperidines substitues
JP6582056B2 (ja)	2014-12-01	2019-09-25	イドーシアファーマシューティカルズリミテッドＩｄｏｒｓｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	Ｃｘｃｒ７受容体調節剤
WO2019145460A1 (fr)	2018-01-26	2019-08-01	Idorsia Pharmaceuticals Ltd	Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide

2017
- 2017-07-27 MA MA45782A patent/MA45782B1/fr unknown
- 2017-07-27 AU AU2017302079A patent/AU2017302079B2/en active Active
- 2017-07-27 SG SG10201906942PA patent/SG10201906942PA/en unknown
- 2017-07-27 EP EP17754283.4A patent/EP3490986B1/fr active Active
- 2017-07-27 CN CN201910748606.6A patent/CN110563717B/zh active Active
- 2017-07-27 UA UAA201901844A patent/UA122987C2/uk unknown
- 2017-07-27 LT LTEP20201796.8T patent/LT3798217T/lt unknown
- 2017-07-27 AR ARP170102126A patent/AR109180A1/es active IP Right Grant
- 2017-07-27 WO PCT/EP2017/068990 patent/WO2018019929A1/fr not_active Ceased
- 2017-07-27 TW TW108111240A patent/TWI691497B/zh active
- 2017-07-27 MX MX2019001042A patent/MX383804B/es unknown
- 2017-07-27 CN CN201780046279.9A patent/CN109563085B/zh active Active
- 2017-07-27 US US16/320,906 patent/US10752620B2/en active Active
- 2017-07-27 DK DK20201796.8T patent/DK3798217T3/da active
- 2017-07-27 RS RS20230297A patent/RS64130B1/sr unknown
- 2017-07-27 ES ES17754283T patent/ES2905755T3/es active Active
- 2017-07-27 PT PT177542834T patent/PT3490986T/pt unknown
- 2017-07-27 PL PL20201796.8T patent/PL3798217T3/pl unknown
- 2017-07-27 UA UAA202002568A patent/UA129887C2/uk unknown
- 2017-07-27 CA CA3032017A patent/CA3032017C/fr active Active
- 2017-07-27 HU HUE17754283A patent/HUE057315T2/hu unknown
- 2017-07-27 PH PH1/2021/552605A patent/PH12021552605A1/en unknown
- 2017-07-27 HR HRP20230313TT patent/HRP20230313T1/hr unknown
- 2017-07-27 SI SI201731053T patent/SI3490986T1/sl unknown
- 2017-07-27 MA MA54653A patent/MA54653B1/fr unknown
- 2017-07-27 SG SG11201900633XA patent/SG11201900633XA/en unknown
- 2017-07-27 PT PT202017968T patent/PT3798217T/pt unknown
- 2017-07-27 LT LTEPPCT/EP2017/068990T patent/LT3490986T/lt unknown
- 2017-07-27 DK DK17754283.4T patent/DK3490986T3/da active
- 2017-07-27 NZ NZ751006A patent/NZ751006A/en unknown
- 2017-07-27 TW TW108111236A patent/TWI691494B/zh active
- 2017-07-27 EA EA201990388A patent/EA037507B1/ru not_active IP Right Cessation
- 2017-07-27 KR KR1020207021496A patent/KR102497095B1/ko active Active
- 2017-07-27 ES ES20201796T patent/ES2954152T3/es active Active
- 2017-07-27 KR KR1020197005980A patent/KR102497091B1/ko active Active
- 2017-07-27 FI FIEP20201796.8T patent/FI3798217T3/fi active
- 2017-07-27 EA EA202091262A patent/EA202091262A1/ru unknown
- 2017-07-27 MY MYPI2019000420A patent/MY198113A/en unknown
- 2017-07-27 HR HRP20211988TT patent/HRP20211988T1/hr unknown
- 2017-07-27 HU HUE20201796A patent/HUE062019T2/hu unknown
- 2017-07-27 RS RS20220082A patent/RS62855B1/sr unknown
- 2017-07-27 MY MYPI2021006484A patent/MY199657A/en unknown
- 2017-07-27 SI SI201731333T patent/SI3798217T1/sl unknown
- 2017-07-27 TW TW106125273A patent/TWI683812B/zh active
- 2017-07-27 JP JP2019503918A patent/JP6655754B2/ja active Active
- 2017-07-27 PL PL17754283T patent/PL3490986T3/pl unknown
- 2017-07-27 EP EP20201796.8A patent/EP3798217B1/fr active Active
2019
- 2019-01-22 CL CL2019000169A patent/CL2019000169A1/es unknown
- 2019-01-23 IL IL264424A patent/IL264424B/en unknown
- 2019-01-24 MX MX2021004000A patent/MX2021004000A/es unknown
- 2019-01-25 PH PH12019500188A patent/PH12019500188A1/en unknown
- 2019-02-27 ZA ZA2019/01256A patent/ZA201901256B/en unknown
- 2019-03-15 JP JP2019048980A patent/JP6655742B2/ja active Active
- 2019-07-01 AR ARP190101842A patent/AR115662A2/es unknown
- 2019-11-15 CL CL2019003281A patent/CL2019003281A1/es unknown
2020
- 2020-07-09 AU AU2020204578A patent/AU2020204578B2/en active Active
- 2020-07-14 US US16/928,787 patent/US11306078B2/en active Active
2021
- 2021-05-05 IL IL282942A patent/IL282942B/en unknown
2022
- 2022-02-21 CY CY20221100143T patent/CY1125016T1/el unknown

Also Published As

Publication number	Publication date
US11306078B2 (en)	2022-04-19
TW201922738A (zh)	2019-06-16
JP6655754B2 (ja)	2020-02-26
AU2017302079B2 (en)	2021-07-22
UA129887C2 (uk)	2025-09-03
PH12021552605A1 (en)	2023-01-23
CL2019000169A1 (es)	2019-06-21
PL3798217T3 (pl)	2023-06-12
EP3798217A1 (fr)	2021-03-31
AU2017302079A1 (en)	2019-03-21
SG10201906942PA (en)	2019-09-27
EA202091262A1 (ru)	2020-08-13
WO2018019929A1 (fr)	2018-02-01
HRP20230313T1 (hr)	2023-05-12
NZ751006A (en)	2021-07-30
TWI683812B (zh)	2020-02-01
IL264424B (en)	2021-08-31
HUE057315T2 (hu)	2022-04-28
SG11201900633XA (en)	2019-02-27
KR20200092420A (ko)	2020-08-03
UA122987C2 (uk)	2021-01-27
HRP20211988T1 (hr)	2022-03-18
LT3798217T (lt)	2023-05-25
KR102497091B1 (ko)	2023-02-06
MX383804B (es)	2025-03-14
MX2019001042A (es)	2019-06-10
US10752620B2 (en)	2020-08-25
CA3032017C (fr)	2023-04-18
AU2020204578A1 (en)	2020-07-30
CY1125016T1 (el)	2023-03-24
EP3798217B1 (fr)	2023-02-22
RS64130B1 (sr)	2023-05-31
ES2905755T3 (es)	2022-04-12
PT3798217T (pt)	2023-05-23
EP3490986A1 (fr)	2019-06-05
CA3032017A1 (fr)	2018-02-01
HUE062019T2 (hu)	2023-09-28
MX2021004000A (es)	2021-06-23
IL264424A (en)	2019-02-28
MA45782A (fr)	2019-06-05
TWI691497B (zh)	2020-04-21
ES2954152T3 (es)	2023-11-20
FI3798217T3 (fi)	2023-05-03
LT3490986T (lt)	2022-02-10
IL282942B (en)	2022-01-01
IL282942A (en)	2021-06-30
CN109563085A (zh)	2019-04-02
JP2019142874A (ja)	2019-08-29
KR102497095B1 (ko)	2023-02-06
CN110563717A (zh)	2019-12-13
AU2020204578B2 (en)	2022-03-10
SI3798217T1 (sl)	2023-05-31
PL3490986T3 (pl)	2022-04-04
JP6655742B2 (ja)	2020-02-26
ZA201901256B (en)	2021-08-25
NZ755815A (en)	2025-02-28
RS62855B1 (sr)	2022-02-28
MY199657A (en)	2023-11-14
MY198113A (en)	2023-08-03
US20200385373A1 (en)	2020-12-10
CN109563085B (zh)	2022-08-09
AR109180A1 (es)	2018-11-07
DK3490986T3 (da)	2022-03-07
MA45782B1 (fr)	2021-12-31
TW201932454A (zh)	2019-08-16
JP2019525927A (ja)	2019-09-12
US20190169180A1 (en)	2019-06-06
EA201990388A1 (ru)	2019-08-30
EP3490986B1 (fr)	2021-11-24
MA54653B1 (fr)	2023-04-28
DK3798217T3 (da)	2023-05-22
PH12019500188A1 (en)	2019-10-21
KR20190034620A (ko)	2019-04-02
CN110563717B (zh)	2022-08-09
TWI691494B (zh)	2020-04-21
AR115662A2 (es)	2021-02-10
CL2019003281A1 (es)	2020-05-04
PT3490986T (pt)	2022-02-01
SI3490986T1 (sl)	2022-02-28
TW201806940A (zh)	2018-03-01
BR112019001551A2 (pt)	2019-05-14
EA037507B1 (ru)	2021-04-06

Publication	Publication Date	Title
MA54653A (fr)	2021-12-29	Modulateurs du récepteur de cxcr7 pipéridine
MA43382A (fr)	2018-10-10	Modulateurs des récepteurs des chimiokines
EP3442971A4 (fr)	2020-01-01	Modulateurs du récepteur des estrogènes
EP3521427A4 (fr)	2020-04-22	Co-récepteur de récepteur odorant
PT3494133T (pt)	2022-09-28	Recetores de células t anti-kras-g12d
DK3359160T3 (da)	2021-11-22	Farnesoid x receptor modulatorer
HUE047929T2 (hu)	2020-05-28	Kiméra antigén receptor
MA55328A (fr)	2022-01-19	Modulateurs de ror-gamma
PT3223850T (pt)	2020-04-13	Receptores de células t anti-kras mutado
MA53943A (fr)	2021-08-25	Modulateurs de ror-gamma
PT3101032T (pt)	2019-04-03	Onjugado de anticorpo anti-her2-fármaco
MA42133A (fr)	2021-06-02	Modulateurs du ccr2
EP3219592C0 (fr)	2024-08-21	Fixation
EP3286210C0 (fr)	2023-10-18	Récepteur de lymphocyte t
EP3565543A4 (fr)	2020-10-14	Modulateurs du récepteur opioïde de type mu
MA52555A (fr)	2021-03-17	Modulateurs du récepteur des oestrogènes
EP3529267C0 (fr)	2023-07-26	Récepteur de lymphocytes t
DK3819287T3 (da)	2023-12-18	Amorft tapentadolphosphat
IL247140A0 (en)	2016-09-29	Pyrazines modulators of gpr6
EP3532062A4 (fr)	2020-04-15	Modulateurs de ror-gamma
EP3421454A4 (fr)	2019-08-14	Dérivé de pipéridine
EP3408286C0 (fr)	2024-11-06	Protéines g
DK3126521T3 (da)	2019-06-17	HNF4G-RSPO2-fusionsgen
PT3302948T (pt)	2020-07-02	Unidade de força de fecho
FR3018292B1 (fr)	2016-03-25	Module de construction du type gabion